Resistance to Antimalarial Monotherapy Is Cyclic.

Area of Science:

• * Parasitology
• * Pharmacology
• * Infectious Diseases

Background:

• * Malaria remains a significant global health threat, causing millions of deaths annually, primarily among children.
• * Drug resistance is a major challenge in malaria control, necessitating continuous monitoring and strategic treatment approaches.

Purpose of the Study:

• * To analyze historical trends in antimalarial drug resistance using citation data.
• * To identify patterns of resistance for common antimalarial drugs over a four-decade period.
• * To evaluate the clinical implications of observed resistance patterns for malaria treatment strategies.

Main Methods:

• * PubMed database was queried for malaria drug resistance data.
• * Yearly citation counts for 14 common antimalarial drugs were plotted.
• * Resistance patterns were analyzed for cyclical and linear trends.
• * Predicted resistance trends were validated against clinical data from the Worldwide Antimalarial Resistance Network (WWARN).

Main Results:

• * Most of the 14 common antimalarial drugs analyzed demonstrated cyclical resistance patterns over four decades.
• * Cyclical resistance involves recurring rises and falls in drug resistance.
• * Artemisinin and dihydroartemisinin showed resistance patterns that could also correlate with a linear increase.
• * The predicted resistance trends aligned with clinical data, validating the methodology.

Conclusions:

• * Cyclical resistance patterns suggest that most antimalarial drugs may remain sustainable in the long term.
• * Understanding cyclic resistance is crucial for clinical practice, discouraging routine monotherapy when resistance is rising.
• * The findings support the use of combination antimalarial drug therapy tailored to distinct phases of resistance.